Product Information
OXCARBAZEPINE 300 MG TABLET is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.1691 per EA under NDC 62756018413. Its NADAC has been published 639 times since Nov 28, 2013.
FDA first approved this application on Oct 9, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
62756018413
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
OXCARBAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA077794FDA Approved
10/9/2007
TE Code
AB
On Market Since
10/9/2007
Pharmacological Classes
Price Statistics
The NADAC for OXCARBAZEPINE 300 MG TABLET has been published 639 times since Nov 28, 2013, and over the history we have for it it has declined 27.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1691 per EA |
|---|---|
| All-time high | $0.2670 (Feb 11, 2015) |
| All-time low | $0.1436 (Feb 20, 2019) |
| 52-week high | $0.1745 |
| 52-week low | $0.1691 |
| Median price | $0.1934 |
| Average price | $0.1926 |
| Largest weekly change | +30.6% (Jan 21, 2015) |
| Weeks tracked | 639 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-2.2%
3Y
-13.1%
5Y
-24.7%
All
-27.5%
Last surveyed Feb 18, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxcarbazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXCARBAZEPINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXCARBAZEPINE 300 MG TABLET, manufactured by Sun Pharmaceutical Industries Inc., is $0.1691 per EA (NDC 62756018413), effective Feb 18, 2026.
How has the price of OXCARBAZEPINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXCARBAZEPINE 300 MG TABLET has declined 27.5%. It has been tracked across 639 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for OXCARBAZEPINE 300 MG TABLET?
Since Nov 28, 2013, the NADAC for OXCARBAZEPINE 300 MG TABLET has ranged from a low of $0.1436 (Feb 20, 2019) to a high of $0.2670 (Feb 11, 2015), with a median of $0.1934 per EA.
Are there cheaper alternatives to OXCARBAZEPINE 300 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXCARBAZEPINE 300 MG TABLET, is $0.1667 per EA — about 1% below OXCARBAZEPINE 300 MG TABLET.
Who manufactures OXCARBAZEPINE 300 MG TABLET?
OXCARBAZEPINE 300 MG TABLET (NDC 62756018413) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.